The company has not filed an annual or quarterly report since its Q3 FY2019 10-Q, filed Nov 5, 2019. Its latest SEC filing is a SC 13G/A from Feb 16, 2021.
10-Q for Q3 FY2019, filed Nov 5, 2019
The sections below describe the company as of the FY2018 annual report.
Sells QBREXZA, a prescription cloth for excessive underarm sweating, and develops injectable and other therapies for chronic skin conditions for patients and physicians.
10-K for FY2018, filed Feb 26, 2019We are a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new…View ↗
QBREXZA, a topical, once-daily anticholinergic cloth that was approved by the U.S. Food and Drug Administration (“FDA”) in June 2018 for…View ↗
Lebrikizumab, a novel, injectable, humanized monoclonal antibody targeting interleukin 13 (“IL-13”) that we are developing for the…View ↗
Early-stage research and development programs in other areas of dermatology.View ↗
Commercialize QBREXZA and any other products for which we secure marketing approval. We are commercializing QBREXZA and currently plan to…View ↗
$42.3M
10-K for FY2018, filed Feb 26, 2019
$42.3M ↗
Dermira sells QBREXZA to wholesalers and a preferred dispensing partner, which supply pharmacies; its commercial team targets dermatologists and other healthcare practitioners.
10-K for FY2018, filed Feb 26, 2019QBREXZA, a topical, once-daily anticholinergic cloth that was approved by the U.S. Food and Drug Administration (“FDA”) in June 2018 for…View ↗
Commercialize QBREXZA and any other products for which we secure marketing approval. We are commercializing QBREXZA and currently plan to…View ↗
We have built a commercial infrastructure to support the commercialization of QBREXZA and the potential commercialization of additional…View ↗
No. It lost $221.5M in FY2018.
10-K for FY2018, filed Feb 26, 2019
10-K for FY2018, filed Feb 26, 2019
−$214MView ↗
10-K for FY2018, filed Feb 26, 2019
−$221.5MView ↗
10-K for FY2018, filed Feb 26, 2019
−$213.7MView ↗
10-Q for Q3 FY2019, filed Nov 5, 2019
−$57.6MView ↗
8-K, filed Feb 20, 2020
On February 10, 2020, Dermira (i) notified The Nasdaq Stock Market (“Nasdaq”) of the anticipated consummation of the Merger and (ii)…View ↗
8-K, filed Jan 10, 2020
On January 10, 2020, Eli Lilly and Company, an Indiana corporation (“Parent”), Bald Eagle Acquisition Corporation, a Delaware corporation…View ↗
Grew. Revenue grew 5.8x in 4 years, from $7.3M in FY2014 to $42.3M in FY2018, about 55% a year.
Product portfolio
The older report describes late-stage candidates for psoriasis, hyperhidrosis and acne, including Cimzia; the latest describes marketed QBREXZA for hyperhidrosis, lebrikizumab for atopic dermatitis, and early research programs.
10-K for FY2015, filed Mar 4, 2016 10-K for FY2018, filed Feb 26, 2019We are a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new…View ↗
QBREXZA, a topical, once-daily anticholinergic cloth that was approved by the U.S. Food and Drug Administration (“FDA”) in June 2018 for…View ↗
Lebrikizumab, a novel, injectable, humanized monoclonal antibody targeting interleukin 13 (“IL-13”) that we are developing for the…View ↗
Early-stage research and development programs in other areas of dermatology.View ↗
Competes with Allergan, Sientra, Cynosure, Candesant Biomedical, Ulthera, Eirion Therapeutics, Medytox, Brickell Biotech, Dr. August Wolff, GlaxoSmithKline, Dermavant Sciences, Atacama Therapeutics, Regeneron, Sanofi-Aventis Groupe, Roche, Novartis, LEO Pharma, Eli Lilly and, Pfizer, and AbbVie
10-K for FY2018, filed Feb 26, 2019Non‑Surgical Office‑Based Procedures. Office‑based procedures have been approved for the treatment of primary axillary hyperhidrosis…View ↗
Loading...
